Scope 3 emissions reporting is becoming a critical compliance requirement for pharmaceutical companies in 2026, driven by the EU’s Corporate Sustainability Reporting Directive and growing investor scrutiny. For pharma supply chains, where cold chain logistics represent a significant share of total emissions, accurate measurement and disclosure are no longer optional. This article covers what Scope 3 emissions mean for pharma, why reporting is now mandatory, and how to measure cold chain emissions effectively.
What are Scope 3 emissions and why do they matter for pharmaceutical companies?
Scope 3 emissions are indirect greenhouse gas emissions that occur across a company’s value chain, outside its own operations. Under the GHG Protocol framework, Scope 1 covers direct emissions from owned sources, Scope 2 covers purchased energy, and Scope 3 covers everything else—from raw material extraction to product distribution and disposal.
For pharmaceutical companies, Scope 3 typically accounts for the vast majority of total emissions. Categories most relevant to pharma include upstream transportation and distribution (Category 4), downstream transportation and distribution (Category 9), and purchased goods and services (Category 1). Cold chain logistics, which often relies on air freight and refrigerated road transport, contributes heavily across these categories.
Monitoring equipment used in those supply chains also falls under Category 1. Electronic data loggers require e-waste disposal, adding a measurable upstream footprint that is frequently overlooked in Scope 3 inventories.
Why is Scope 3 emissions reporting becoming mandatory for pharma supply chains in 2026?
The regulatory landscape has shifted significantly, with 2026 marking a concrete compliance deadline for many pharmaceutical companies. The EU’s Corporate Sustainability Reporting Directive (CSRD) requires large companies to report Scope 3 emissions as part of their annual sustainability disclosures, with the first reports covering financial year 2025 due in 2026.
In parallel, the SEC’s climate disclosure rules are increasing pressure on US-listed pharma companies to disclose material climate risks, including supply chain emissions. Beyond regulation, major procurement teams and institutional investors are now requesting Scope 3 data as part of supplier qualification and ESG scoring processes.
For mid-to-large pharmaceutical companies operating internationally, this means cold chain logistics partners must be able to provide reliable emissions data—and internal teams need the processes in place to collect, verify, and report it credibly.
How do you accurately measure cold chain emissions across a global pharma supply chain?
Measuring cold chain Scope 3 emissions requires choosing the right calculation method for the data available. The three main approaches are spend-based (using financial spend as a proxy), activity-based (using actual transport distances, modes, and load factors), and supplier-specific (using primary data provided directly by logistics partners).
Activity-based methods produce more accurate results but depend on detailed shipment data across road, sea, air, and rail transport. Air freight, common in pharma cold chains, carries a significantly higher emission factor than sea or road, making transport mode data particularly important to capture correctly.
Engaging logistics partners in structured data sharing is often the biggest practical challenge. Providing partners with clear data templates and aligning on emission factor sources helps reduce inconsistency. Temperature monitoring records from shipments can also support emission estimates by confirming transport durations and conditions, improving the reliability of activity-based calculations.
How Tapp helps pharmaceutical companies reduce and report cold chain Scope 3 emissions
As the only provider of the most sustainable paper data logger, Tapp has developed a cold chain monitoring solution that directly supports pharma sustainability and compliance goals. Here is how it addresses key Scope 3 challenges:
- Reduces Scope 3 Category 1 footprint: Tapp’s paper-based data loggers are made from agricultural-waste paper and are recyclable through standard paper waste streams globally, eliminating the e-waste burden of single-use electronic loggers.
- Lithium-free design: Unlike single-use electronic loggers that rely on lithium batteries, paper-based loggers use a lithium-free power source, reducing upstream material emissions and avoiding hazardous waste disposal.
- Cloud-based transport documentation: Data syncs automatically to a cloud dashboard the moment a label is read, giving sustainability teams accurate, timestamped shipment records to support emission calculations.
- No-app NFC readability: Any NFC-enabled smartphone can read the label instantly, removing infrastructure barriers for logistics partners and making data collection practical across diverse international supply chains.
- EN 12830-certified accuracy: Certified temperature data supports audit-ready compliance reporting, giving quality and sustainability managers documentation they can rely on for regulatory submissions.
If you are a pharma quality or sustainability manager looking to strengthen your Scope 3 reporting while reducing cold chain waste, get in touch with Tapp to explore how paper-based monitoring can support your 2026 compliance goals.
